Cargando…

Clinical Outcomes of a Treat and Extend Regimen with Intravitreal Aflibercept Injections in Patients with Diabetic Macular Edema: Experience in Clinical Practice

INTRODUCTION: Treat-and-extend (T&E) and pro re nata (PRN; ‘as needed’) regimens of intravitreal anti-vascular endothelial growth factor (VEGF) treatment have been found to reduce the injection burden on patients and improve the cost effectiveness of the treatment of macular edema. The aim of th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Curry, Beverley A., Sanfilippo, Paul G., Chan, Sarah, Hewitt, Alexander W., Verma, Nitin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7054518/ https://www.ncbi.nlm.nih.gov/pubmed/31755040 http://dx.doi.org/10.1007/s40123-019-00224-x

Ejemplares similares

Prospective Clinical Trial of Intravitreal Aflibercept Treat-and-extend Regimen for Diabetic Macular Edema: 1-Year Outcomes
por: Mieno, Hiroki, et al.
Publicado: (2020)

Clinical Application of Intravitreal Aflibercept Injection for Diabetic Macular Edema Comparing Two Loading Regimens
por: Chung, Yoo-Ri, et al.
Publicado: (2023)

Comparison of 2-Year Outcomes between Intravitreal Ranibizumab and Intravitreal Aflibercept for Diabetic Macular Edema with “Treat-and-Extend” Regimen—Its Usefulness and Problems
por: Chujo, Shinichiro, et al.
Publicado: (2020)

Changes in metamorphopsia following intravitreal aflibercept injection for diabetic macular edema
por: Murakami, Tomoya, et al.
Publicado: (2022)

Outcomes of a 2-year treat-and-extend regimen with aflibercept for diabetic macular edema
por: Hirano, Takao, et al.
Publicado: (2021)

Randomized clinical trial comparing intravitreal aflibercept combined with subthreshold laser to intravitreal aflibercept monotherapy for diabetic macular edema
por: Tatsumi, Tomoaki, et al.
Publicado: (2022)

Effect of intravitreal aflibercept on recalcitrant diabetic macular edema
por: Klein, Kendra A., et al.
Publicado: (2017)

Intravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema
por: Fouda, Sameh Mosaad, et al.
Publicado: (2017)

One-Year Outcome of Aflibercept Intravitreal Injection in Vitrectomized Eyes with Diabetic Macular Edema
por: Tran, Thi Ha Chau, et al.
Publicado: (2021)

Two-Year Outcome of Aflibercept Intravitreal Injection in Vitrectomized Eyes with Diabetic Macular Edema
por: Tran, Thi Ha Chau, et al.
Publicado: (2022)

Clinical Comparative Study of Intravitreal Injection of Triamcinolone Acetonide and Aflibercept in the Treatment of Diabetic Retinopathy Cystoid Macular Edema
por: Zhu, Yanxia, et al.
Publicado: (2022)

Renal thrombotic microangiopathy and nephrotic proteinuria induced by intravitreal injection of aflibercept for diabetic macular edema
por: Kikuchi, Yawara, et al.
Publicado: (2022)

Intravitreal ziv-aflibercept for macular edema following retinal vein occlusion
por: Paulose, Remya, et al.
Publicado: (2016)

Comparisons of Efficacy of Intravitreal Aflibercept and Ranibizumab in Eyes with Diabetic Macular Edema
por: Shimizu, Norihiro, et al.
Publicado: (2017)

Therapeutic effect of simultaneous intravitreal dexamethasone and aflibercept on diabetic macular edema
por: Lin, Tai-Chi, et al.
Publicado: (2021)

Role of peripheral pan-retinal photocoagulation in diabetic macular edema treated with intravitreal ziv-aflibercept
por: Mansour, Ahmad M, et al.
Publicado: (2019)

Therapeutic effect of cataract surgery with simultaneous intravitreal injection of aflibercept on diabetic macular edema: An observational study
por: Yen, Chu-Yu, et al.
Publicado: (2022)

Correction: Renal thrombotic microangiopathy and nephrotic proteinuria induced by intravitreal injection of aflibercept for diabetic macular edema
por: Kikuchi, Yawara, et al.
Publicado: (2022)

The clinical utility of aflibercept for diabetic macular edema
por: Stewart, Michael W
Publicado: (2015)

Dosing Regimens of Intravitreal Aflibercept for Diabetic Macular Edema Beyond the First Year: VIOLET, a Prospective Randomized Trial
por: Garweg, Justus G., et al.
Publicado: (2022)

Intravitreal aflibercept for diabetic macular edema in real-world clinical practice in Japan: 24-month outcomes
por: Sugimoto, Masahiko, et al.
Publicado: (2022)

Switching to Aflibercept in Diabetic Macular Edema Not Responding to Ranibizumab and/or Intravitreal Dexamethasone Implant
por: Herbaut, Antoine, et al.
Publicado: (2017)

EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT USING A TREAT-AND-EXTEND REGIMEN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: The ARIES Study: A Randomized Clinical Trial
por: Mitchell, Paul, et al.
Publicado: (2021)

Two-year outcomes of intravitreal aflibercept in a Swiss routine treat and extend regimen for patients with neovascular age-related macular degeneration
por: Ebneter, Andreas, et al.
Publicado: (2020)

A Treat-and-Extend Regimen of Intravitreal Brolucizumab for Exudative Age-Related Macular Degeneration Refractory to Aflibercept: A 12-Month Result
por: Kikushima, Wataru, et al.
Publicado: (2023)

One-Year Results of a Treat-and-Extend Regimen of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy
por: Tamachi, Tomoko, et al.
Publicado: (2020)

Intravitreal aflibercept for the treatment of patients with diabetic macular edema in routine clinical practice in Latin America: the AQUILA study
por: Rodríguez, Francisco J., et al.
Publicado: (2022)

Correction to: Intravitreal aflibercept for diabetic macular edema in real‑world clinical practice in Japan: 24‑month outcomes
por: Sugimoto, Masahiko, et al.
Publicado: (2022)

Two-year outcomes of the treat-and-extend regimen using aflibercept for treating diabetic macular oedema
por: Kim, Yu Cheol, et al.
Publicado: (2020)

Efficacy of Modified Treat-and-Extend Aflibercept Regimen for Macular Edema Due to Branch Retinal Vein Occlusion: 1-Year Prospective Study
por: Arai, Yusuke, et al.
Publicado: (2020)

Intravitreal ziv-aflibercept for recurrent macular edema secondary to central retinal venous occlusion
por: Chhablani, Jay
Publicado: (2015)

Effects of Intravitreal Aflibercept on Retinal Function and Improvement of Macular Edema Associated With Diabetic Retinopathy
por: Ichio, Atsushi, et al.
Publicado: (2020)

Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema: Exploratory Retrospective Analysis
por: Pessoa, Bernardete, et al.
Publicado: (2021)

Angiographic biomarkers are significant predictors of treatment response to intravitreal aflibercept in diabetic macular edema
por: Hein, Martin, et al.
Publicado: (2023)

Predictive factors for treatment outcomes with intravitreal anti-vascular endothelial growth factor injections in diabetic macular edema in clinical practice
por: Gurung, Rajya L, et al.
Publicado: (2023)

Four-year outcomes of intravitreal aflibercept treatment for neovascular age-related macular degeneration using a treat-and-extend regimen in Japanese patients
por: Ishibashi, Koki, et al.
Publicado: (2021)

Intravitreal injection of Bevacizumab in diabetic macular edema
por: Ateeq, Asim, et al.
Publicado: (2014)

Efficacy of Modified Treat-and-Extend Regimen of Aflibercept for Macular Edema from Branch Retinal Vein Occlusion: 2-Year Prospective Study Outcomes
por: Arai, Yusuke, et al.
Publicado: (2021)

Initiation of intravitreal aflibercept injection treatment in patients with diabetic macular edema: a review of VIVID-DME and VISTA-DME data
por: Ziemssen, Focke, et al.
Publicado: (2016)

CHANGES IN PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, AFLIBERCEPT, OR RANIBIZUMAB FOR DIABETIC MACULAR EDEMA
por: Hirano, Takao, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_snd09lo8p2ujp258l52uehh3gc